Overview


According to FutureWise analysis the market for Relapsing-Remitting Multiple Sclerosis in 2023 is US$ 4.32 billion, and is expected to reach US$ 5.61 billion by 2031 at a CAGR of 3.30%.

Multiple sclerosis can also be called relapsing-remitting multiple sclerosis. This is the most common form of multiple sclerosis (MS), accounting for around 85% of all diagnoses. People with RRMS experience relapses and periods of remission. MS is a progressive, chronic condition in the central nervous system (CNS). Your immune system attacks myelin which protects nerve fibers. Myelin damage causes nerve inflammation which makes it more difficult for your brain and other parts of your body to communicate with each other. The exact causes of RRMS or other forms of MS are currently unknown. A combination of environmental and genetic factors such as smoking, vitamin D deficiencies, and viral infections may play a part. MS is not curable. However, treatment can be used to manage symptoms, stop relapses and slow down progression. There are many medications and treatments available. Some medications may be helpful for symptoms such as fatigue or stiffness. Mobility problems or weakness can be treated by a physiotherapist.

A multiple sclerosis is a form of multiple sclerosis. People with RRMS experience relapses and recovery periods. Multiple sclerosis is a chronic, degenerative disorder in the central nervous system, where the immune system attacks myelin, which is the insulating coating surrounding nerve fibers. Multiple sclerosis (MS), a chronic autoimmune and inflammatory demyelinating central nervous system disease, is characterized by neurological symptoms that affect the motor, sensory and visual systems. Multiple sclerosis (MS) symptoms and impairments can vary and include fatigue, difficulty moving, imbalance, numbness and pain, bowel or bladder dysfunction, sexual dysfunction, cognitive impairment, and sexual dysfunction. MS can be classified as progressive, secondary, or relapsing-remitting (RRMS). Due to the complex course of MS, the indistinct progression of the disease, and the lack of diagnostic and biomarker tools, the transition from relapsing to committing multiple sclerosis (SPMS), remains a clinical challenge. Multiple sclerosis is a chronic, immune-mediated, immuno-mediated disease that causes nerve cell damage in the brain and spinal cord.

It can cause neurodegeneration, demyelination, and axonal transsection. Some of the most popular therapies include infused, oral, and infused medications as well as muscle relaxants, antidepressants, and physical therapy. Glatiramer acetate and interferon beta are injectable therapies. They can be administered under the skin or into the muscles. Oral medications include teriflunomide and dimethyl fumarate; intravenous infusions include alemtuzumab, natalizumab, and Teriflunomide. Multiple Sclerosis (MS), a chronic, inflammatory, and immune-mediated demyelinating central nervous system disease (CNS) affect the brain, spine cord, and optic nerves, and can be triggered by inflammation, and immune-mediated processes. Multiple Sclerosis can cause a variety of functional symptoms, including abnormal gait, weakness, muscle weakness, fatigue, and spasticity. Multiple sclerosis is a condition where your immune system attacks the central nervous system and damages the myelin that protects the nerve fibers. MS is a disease that can be caused by environmental factors, according to experts.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Relapsing-Remitting Multiple Sclerosis Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Relapsing-Remitting Multiple Sclerosis Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Biogen
  • Novartis
  • Roche
  • Bayer Healthcare
  • Pfizer
  • Merck & Co.
  • Sanofi
  • Teva
  • GalxoSmithKline
  • Acorda Therapeutics Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Treatment

  • Immunomodulating Drugs
  • NrF2 Activators
  • Interferons
  • Others

By Route of Administration

  • Oral
  • Intravenous

By End User

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Relapsing-Remitting Multiple Sclerosis Market By Treatment, By Route of Administration, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Relapsing-Remitting Multiple Sclerosis Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Relapsing-Remitting Multiple Sclerosis Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Relapsing-Remitting Multiple Sclerosis Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Relapsing-Remitting Multiple Sclerosis Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Immunomodulating Drugs
        2. NrF2 Activators
        3. Interferons
        4. Others

  • 8.   Relapsing-Remitting Multiple Sclerosis Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Intravenous

  • 9.   Relapsing-Remitting Multiple Sclerosis Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Others

  • 10.   North America Relapsing-Remitting Multiple Sclerosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Relapsing-Remitting Multiple Sclerosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Relapsing-Remitting Multiple Sclerosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Relapsing-Remitting Multiple Sclerosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Relapsing-Remitting Multiple Sclerosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Biogen
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Novartis
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Roche
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bayer Healthcare
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Merck & Co.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Sanofi
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Teva
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. GalxoSmithKline
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Acorda Therapeutics Inc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients